Merck bags Recarbrio FDA approval for urinary tract and intra-abdominal infections
Recarbrio FDA approval : Merck & Co. has secured approval from the US Food and Drug Administration (FDA) for its antibacterial drug product Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of adults having complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Recarbrio is a three-drug combination injection made up of the FDA-approved […]